News & Press Releases

Integrity Applications to Present at the Sidoti & Company Semi-Annual Micro-Cap Conference in New York City on January 13, 2014

January 8th, 2014

http://www.businesswire.com/news/home/20140108005181/en/Integrity-Applications-Present-Sidoti-Company-Semi-Annual-Micro-Cap#.Us1MOhYQSlI

Integrity Applications to Present at the Sidoti & Company Semi-Annual Micro-Cap Conference in New York City on January 13, 2014

Sidoti & Company Semi-Annual Microcap Conference

ASHKELON, Israel–()–Integrity Applications, Inc. (OTCQB:IGAP), developer of the GlucoTrack® model DF-F non-invasive blood glucose measurement device, today announced that Avner Gal, its President and CEO, will be presenting at Sidoti & Company’s Semi-Annual Micro-Cap Conference at the Grand Hyatt Hotel in New York, New York on Monday, January 13, 2014. He is scheduled to present at 11:20 AM ET in the Estate 2 Room.

During his presentation, Mr. Gal will discuss the Company’s CE Marked GlucoTrack model DF-F non-invasive glucose monitoring device, designed for spot measuring. GlucoTrack aims to help people with diabetes obtain blood glucose level measurements without the pain, inconvenience, incremental cost and difficulty of conventional (invasive) spot finger stick devices.

Mr. Gal will be available for one-on-one meetings during the conference. If you are interested in meeting with him, please either contact your representative at Sidoti, or call Tom Caden of Dian Griesel Int’l. at 212-825-3210.

About Integrity Applications, Inc.

Integrity Applications, Inc. is a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Integrity Applications has developed the GlucoTrack model DF-F non-invasive glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level measurements without the pain, inconvenience, incremental cost and difficulty of conventional (invasive) spot finger stick devices. Integrity Applications works primarily through its wholly-owned Israeli subsidiary, A.D. Integrity Applications, Ltd. For more information please visit www.integrity-app.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “will,” and “aims,” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications’ results include, but are not limited to, the ability of Integrity applications to successfully commercialize the GlucoTrack DF-F; the ability of the GlucoTrack DF-F to achieve acceptable pricing, adequate third party reimbursement or market acceptance; the ability of Integrity Applications to manage its growth and the expansion of its operations to include commercialization activities; risks relating to the use of third party manufacturers; risks relating to the development of Integrity Applications’ sales, marketing and distribution capability, either on its own or through collaborations with marketing partners; and the additional risk factors described in Integrity Applications’ filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2012.

Contacts

Integrity Applications
Avner Gal, +972 (8) 675-7878
President and CEO
info@integrity-app.com
or
Dian Griesel Int’l.
Investor Relations:
Cheryl Schneider, +1 212-825-3210
cschneider@dgicomm.com
or
Public Relations:
Susan Forman, +1 212-825-3210
sforman@dgicomm.com
or
Laura Radocaj, +1 212-825-3210
lradocaj@dgicomm.com

Back to all news & press releases

Sign up to our newsletter
To receive occasional news updates

LinkedIn Facebook Twitter